Login
$ANIK
$12.92 -$0.48 (3.58%) Live

$ANIK 8-K SEC Filings

Filed On Filing
06 Nov 2026 8-K: Results of Operations and Financial Condition

Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in IntegrityTM Revenue

29 Jul 2026 8-K: Results of Operations and Financial Condition

Commercial Channel Revenue Increased 17% to a Record $13.9 Million

14 Jul 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

This FIFTH AMENDMENT TO CREDIT AGREEMENT, dated as of July 10, 2026 (this “Fifth Amendment”), is entered into among ANIKA THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), the Subsidiary Guarantors party hereto (if any), each ...

23 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Anika Therapeutics, Inc. sets forth herein the terms of its 2017 Omnibus Incentive Plan.

29 Apr 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing

26 Feb 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target

08 Jan 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

This Employment Agreement (“Agreement”) shall be effective as of February 1, 2026 between Anika Therapeutics, Inc., a Delaware corporation (the “Company”), and Steve Griffin (the “Executive”).

05 Nov 2025 8-K: Results of Operations and Financial Condition; Other Events

Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth

30 Jul 2025 8-K: Results of Operations and Financial Condition

Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025

30 Jul 2025 8-K: Regulation FD Disclosure

Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update

24 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Anika Therapeutics, Inc. sets forth herein the terms of its 2017 Omnibus Incentive Plan.

09 May 2025 8-K: Results of Operations and Financial Condition

Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025

10 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation

On April 4, 2025, Anika Therapeutics, Inc. (the “Company”) announced the departure of Anne Nunes, Chief Operations Officer, effective April 25, 2025.

12 Mar 2025 8-K: Results of Operations and Financial Condition

Full Year 2024 results in line with guidance with Commercial Channel revenue up 17%

11 Mar 2025 8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure

Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio

31 Oct 2024 8-K: Results of Operations and Financial Condition

Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds

31 Oct 2024 8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure

Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile

08 Aug 2024 8-K: Results of Operations and Financial Condition

Expanded Regenerative Solutions portfolio with full market release of the Integrity™ Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating significant market demand

11 Jul 2024 8-K: Submission of Matters to a Vote of Security Holders

Anika Therapeutics, Inc., or the Company, held the 2024 Annual Meeting of Stockholders, or the Annual Meeting, on July 9, 2024. The board of directors of the Company, or the Board, solicited proxies for the Annual Meeting pursuant to the...

28 May 2024 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more

This COOPERATION AGREEMENT (this “Agreement”) is made and entered into as of May 28, 2024, by and between Anika Therapeutics, Inc., a Delaware corporation (the “Company”), Caligan Partners LP, Caligan Partners Master Fund LP and David Jo...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support